Candiolo Cancer Institute - IRCCS
11
4
5
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
9%
1 trials in Phase 3/4
20%
1 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
Immunological Phenotype of Desmoid-fibromatosis-affected Patients.
Role: collaborator
A Comparative Study of Nipple Sensation Preservation After Nipple-Sparing Mastectomy With Conventional, Endoscopic, Robotic Techniques
Role: lead
Sexual Dysfunction Check-up in Premenopausal Breast Cancer Survivors Taking Endocrine Therapy: A Cross-Sectional Study
Role: lead
PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer
Role: collaborator
GENomic PROfilation for Therapeutic Purposes in SARComas and Molecular Tumor Board (MTB): Retrospective/Prospective Study in Referral Centers
Role: collaborator
Longitudinal Evaluation of Intestinal, Haematological and Urinary Toxicity From Pelvic Irradiation for Prostate Cancer
Role: collaborator
Complete Mesocolic Excision in Comparison With Conventional Surgery for the Right Colon Cancer
Role: collaborator
Dysplasia Detection and Helicobacter Pylori Eradication
Role: collaborator
Participation and Detection Rate of Screening CT Colonography and Screening Sigmoidoscopy
Role: collaborator
Clinical Validation of the M5L Lung CAD
Role: lead
Impact of Computer-Aided Detection (CAD) as Second Reader in CT Colonography
Role: collaborator
All 11 trials loaded